Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Breast Neoplasms × camrelizumab × Clear all

Phase

Phase 2 10 Phase 1 2 Phase 3 1 Phase 2/3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Hepatocellular 3 Uterine Cervical Neoplasms 1 Triple Negative Breast Neoplasms 1 Pancreatic Neoplasms 1 Non-squamous Non-small Cell Lung Cancer 1 Neoplasms 1 Nasopharyngeal Carcinoma 1 Liver Neoplasms 1 Hodgkin Disease 1 Hepatoblastoma 1 Breast Neoplasms 1 Advanced Solid Tumor 1 Adenocarcinoma 1

Interventions

Capecitabine 15 Paclitaxel 11 Docetaxel 10 Cyclophosphamide 10 Epirubicin 8 Gemcitabine 7 Letrozole 6 Doxorubicin 6 Carboplatin 6 Trastuzumab 5 Vinorelbine 4 pertuzumab 3 exemestane 3 Cisplatin 3 AC protocol 3 130-nm albumin-bound paclitaxel 3 Thiotepa 2 Taxes 2 Tamoxifen 2 Neoadjuvant Therapy 2 Melatonin 2 Lapatinib 2 Goserelin 2 Fluorouracil 2 Drug Therapy 2 Albumin-Bound Paclitaxel 2 Ado-Trastuzumab Emtansine 2 taxane 1 soluble LAG-3 protein, human 1 pyrotinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04803539 2023-02-21

Artemis

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2/3 Recruiting

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡